The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines

Acta Haematologica

Volumn 102, Issue 2, 1999, Pages 66-71

  Turnbull, J L ^a   Patchen, M L ^b   Scadden, D T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Alpha Beta Technology Inc   (United States)

Author keywords

Cytokines; Glucans; Hematopoiesis; Myelopoiesis; Polysaccharide; Stem cells

Indexed keywords

BETA GLUCAN; CD34 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; STEM CELL FACTOR;

ARTICLE; BONE MARROW; CONTROLLED STUDY; HEMATOPOIESIS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MYELOPOIESIS; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; BETA-GLUCANS; BONE MARROW CELLS; CYTOKINES; GLUCANS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INTERLEUKIN-3; LEUKOPOIESIS; RECOMBINANT PROTEINS; STEM CELL FACTOR; STIMULATION, CHEMICAL;

EID: 0032837225     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040972     Document Type: Article

References (23)

1. DiLuzio NR, McNamee R, Browder WI, Williams D: Inhibition of tumor growth and enhancement of survival in four syngeneic murine tumor models. Cancer Treat Rep 1978;62: 1857-1866.
2. Mansell PWA, DiLuzio NR, McNamee R, Rowden G, Proctor JW: Recognition factors and nonspecific macrophage activation in the treatment of neoplastic disease. Ann NY Acad Sci 1976;277:20-44.
3. Mansell PW, Ichinose H, Reed RJ, Krementa ET, McNamee R, DiLuzio NR: Macrophage mediated destruction of human malignant cells in vivo. J Natl Cancer Inst 1975;54:571-580.
4. Williams DL, Sherwood ER, Browder W, McNamee RB, Jones EL, Rakinic J, Di Luzio NR: Effect of glucan on neutrophil dynamics and immune function in Escherichia coli peritonitis. J Surg Res 1988;44:54-61.
5. DiLuzio NR, Williams DL, McNamee RB, Edwards BF, Kitahama A: Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int J Cancer 1979;24: 773-779.
6. DiLuzio NR, Williams DL: Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leukemic mice. Infect Immun 1978;20:804-810.
7. Kokoshis PL, Williams DL, Cook JA, DiLuzio NR: Increased resistance to Staphylococcus aureus infection and enhancement in serum lysozyme activity by glucan. Science 1978;199: 1340-1342.
8. Burgaleta C, Territo MC, Quan SG, Golde DW: Glucan-activated macrophages: Functional characteristics and surface morphology. J Reticuloendothel Soc 1978;23:195-204.
9. Burgaleta C, Golde DW: Effect of glucan on granulopoiesis and macrophage genesis in mice. Cancer Res 1977;37:1739-1742.
10. Patchen ML, Lotzova E: Modulation of murine hemopoiesis by glucan. Exp Hematol 1980;8: 409-422.
11. Patchen ML, MacVittie TJ: Dose-dependent responses of murine pluripotent stem cells and myeloid and erythroid progenitor cells following administration of the immunomodulating agent glucan. Immunopharmacology 1983;5: 303-313.
12. Patchen ML, MacVittie TJ: Temporal response of murine pluripotent stem cells and myeloid and erythroid progenitor cells to low-dose glucan treatment. Acta Haematol 1983;70:281-288.
13. Niskanen EO, Burgaleta C, Cline MJ, Golde DW: Effect of glucan, a macrophage activator, on murine hemopoietic cell proliferation in diffusion chambers in mice. Cancer Res 1978;38: 1406-1409.
14. Onderdonk AB, Cisneros RL, Hinkson P, Ostroff G: Anti-infective effect of poly-β1,3 glucopyranose glucan in vivo. Infect Immun 1992; 60:1642-1647.
15. Patchen ML, MacVittie TJ, Solberg BD, Souza LM: Survival enhancement and hematopoietic regeneration following radiation exposure: Therapeutic approach using glucan and granulocyte colony-stimulating factor. Exp Hematol 1990;18:1042-1048.
16. Patchen ML, D'Alesandro MM, Brook I, Blakely WF, MacVittie TJ: Glucan: Mechanisms involved in its 'radioprotective' effect. J Leukoc Biol 1987;42:95-105.
17. Patchen ML, Lotzova E: The role of macrophages and T-lymphocytes in glucan-mediated alteration of murine hemopoiesis. Biomedicine 1981;34:71-77.
18. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, et al: A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994;129:1204-1210.
19. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrain B, Forse RA: Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994;220:601-609.
20. Bleicher P, Mackin W: Betafectin PGG-glucan: A novel carbohydrate immunomodulator with anti-infective properties. J Biotechnol Healthcare 1995;2/2:207-222.
21. Patchen ML, Bleicher P, Liang J, Vaudrain T, Maschek BJ, Jackson JD: Mobilization of peripheral blood progenitor cells by Belafectin PGG-glucan. Exp Hematol 1996;24:1032.
22. Lane RD: A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas. J Immunol 1985;81:223-228.
23. Adams DS, Pero SC, Petra JD, Nathans R, Mackin WM, Wakshull E: PGG-glucan activates NF-kappaB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. J Leukoc Biol 1977;62:865-873.